

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number

WO 2022/086953 A9

(43) International Publication Date
28 April 2022 (28.04.2022)

(51) International Patent Classification:

A61K 38/30 (2006.01) A61P 11/00 (2006.01)
A61K 38/17 (2006.01) A61P 25/00 (2006.01)
A61K 47/26 (2006.01) A61P 9/00 (2006.01)

(21) International Application Number:

PCT/US2021/055598

(22) International Filing Date:

19 October 2021 (19.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/093,696 19 October 2020 (19.10.2020) US

(71) Applicant: **OAK HILL BIO LIMITED** [GB/GB]; 3rd
Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT
(GB).

(72) Inventors: **SALAMAT-MILLER, Nazila**; c/o Shire Human Genetic Therapies, Inc., 300 Shire Way, Lexington, MA 02421 (US). **TAYLOR, Katherine**; c/o Shire Human Genetic Therapies, Inc., 300 Shire Way, Lexington, MA 02421 (US). **HE, Bing**; c/o Shire Human Genetic Therapies, Inc., 300 Shire Way, Lexington, MA 02421 (US). **BHAT-TACHARYA, Indranil**; c/o Shire Human Genetic Therapies, Inc., 300 Shire Way, Lexington, MA 02421 (US). **HAN, Linda**; c/o Shire Human Genetic Therapies, Inc., 300 Shire Way, Lexington, MA 02421 (US). **AMSDEN, Benita**; c/o Shire Human Genetic Therapies, Inc., 300 Shire Way, Lexington, MA 02421 (US). **KRANZ, James**; c/o Shire Human Genetic Therapies, Inc., 300 Shire Way, Lexington, MA 02421 (US).

(74) Agent: **PRAIRIE, Nicholas C.** et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

07 July 2022 (07.07.2022)

(15) Information about Correction:

see Notice of 07 July 2022 (07.07.2022)

(54) Title: COMPOSITIONS SUITABLE FOR USE IN NEONATES

(57) Abstract: The present invention provides stable, pure and potent compositions optimized for administration to neonates and/or preterm infants, and use of the same in methods for treating intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), and/or chronic lung disease of prematurity (CLD), comprising administering to a subject in need of treatment a pharmaceutical composition comprising insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), and a polysorbate 20 surfactant at high effective doses in low volumes in an infant resulting high serum IGF-1 exposure and treatment of IVH, BPD and/or CLD. In some aspects, provided herein are methods for manufacturing the compositions comprising a single-use bag, wherein the compositions have improved stability, reduced oxidation and increased potency. In some aspects, the methods provided result in reduced incidence of symptoms and features of intraventricular hemorrhage, bronchopulmonary dysplasia, right ventricular hypertrophy (RVH), pulmonary hypertension (PH), necrotizing enterocolitis, or chronic lung disease of prematurity.

WO 2022/086953 A9